More than 42 million Americans are currently infected with HPV types known to cause disease, and about 13 million new infections occur each year. It is the most common sexually transmitted infection in the United States by a wide margin, and roughly 85% of people will get at least one HPV infection during their lifetime.
How Common HPV Really Is
National survey data from the CDC puts genital HPV prevalence at 42.5% among U.S. adults aged 18 to 59. That means nearly half of all adults in that age range are carrying some type of HPV at any given time. Most of them have no symptoms and no idea they’re infected. The virus spreads through skin-to-skin sexual contact, and because it so often causes zero noticeable problems, it circulates widely without people ever realizing they’ve had it.
HPV isn’t a single virus. There are more than 200 types, and the 37 most commonly tested for fall into two broad categories: high-risk types that can eventually lead to cancer, and low-risk types that can cause genital warts but pose no cancer risk. About 22.7% of adults aged 18 to 59 carry at least one high-risk type. The rest carry only low-risk strains or types with no known health consequences at all.
Differences Between Men and Women
Men are slightly more likely to be infected than women. Genital HPV prevalence is 45.2% among men compared to 39.9% among women in the same age range. The gap is even more pronounced for oral HPV: 11.5% of men carry an oral infection versus 3.3% of women. For high-risk oral types specifically, the rate is 6.8% in men and just 1.2% in women.
This disparity matters because HPV-related throat cancers (oropharyngeal cancers) now outnumber cervical cancers in the U.S., and they overwhelmingly affect men. About 16,000 throat cancers caused by HPV are diagnosed each year, compared to 11,100 cervical cancers. Women benefit from routine cervical screening that catches precancerous changes early, while there’s no equivalent screening test for men.
Most Infections Clear on Their Own
The body’s immune system eliminates the vast majority of HPV infections without any treatment. Oral HPV infections are especially short-lived, with a mean clearance time of about 46 days. Only 16% of oral infections persist long enough to still be detectable at a follow-up visit. Genital infections take somewhat longer, averaging around 87 days to clear, with about 56% still present at a subsequent check.
The infections that matter most are the ones that don’t clear. When a high-risk HPV type persists for years, it can cause cells to change in ways that eventually become cancerous. HPV is responsible for roughly 39,300 cancers in the U.S. each year, including cervical, throat, and anal cancers. About 91% of anal cancers and nearly all cervical cancers are caused by the virus. But these outcomes represent a tiny fraction of all HPV infections. The overwhelming majority resolve quietly.
High-Risk Versus Low-Risk Types
Of the HPV types that cause problems, types 16 and 18 are the most dangerous. They’re responsible for the majority of HPV-related cancers. Types 6 and 11, on the other hand, are low-risk. They cause more than 90% of genital warts cases but don’t lead to cancer. A person can carry multiple HPV types at the same time, and having a low-risk type doesn’t protect against acquiring a high-risk one later.
About one in four adults carries a high-risk genital HPV type (25.1% of men, 20.4% of women). That’s a large number of people, but only a small percentage of persistent high-risk infections will ever progress to cancer, typically over the course of 10 to 20 years. This long timeline is what makes cervical screening so effective: it catches precancerous changes years before they become dangerous.
Vaccination Has Dramatically Reduced Infections
The HPV vaccine, introduced in 2006, has reshaped infection rates among young people. Among females aged 14 to 19, prevalence of the four HPV types targeted by the vaccine dropped 88%, falling from 11.5% before the vaccine era to just 1.1% by 2015 to 2018. Among women aged 20 to 24, the decline was 81%, from 18.5% down to 3.3%.
These reductions are remarkable given that vaccination coverage in the U.S. still isn’t universal. The vaccine works best when given before any exposure to HPV, which is why it’s recommended at age 11 or 12, though it can be given as early as 9 and is approved through age 45. The current vaccine protects against nine HPV types, covering the two that cause the most cancers and the two that cause the most genital warts.
Why the Numbers Feel Surprising
If nearly half of adults carry genital HPV and 85% will get it at some point in their lives, you might wonder why it doesn’t get more attention. The answer is that HPV behaves differently from most infections people worry about. It usually produces no symptoms, clears without treatment, and only rarely leads to serious health problems. There’s no routine HPV test for men, and genital HPV testing in women is typically done only as part of cervical cancer screening starting at age 25 or 30, depending on guidelines.
The practical reality is that HPV is so common it’s considered a near-universal consequence of sexual activity. The goal of public health efforts isn’t to eliminate every infection but to prevent the small percentage that lead to cancer, primarily through vaccination and cervical screening.